Janssen Presents First Data from MajesTEC-2 Trial of : vimar

Janssen Presents First Data from MajesTEC-2 Trial of

Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen1 BEERSE, Belgium, Dec. 10, 2022 (GLOBE NEWSWIRE) -- The...

Related Keywords

United States , Belgium , Beerse , Region Flamande , American , Emma Searle , Sen Zhuang , Edmond Chan , American Society Of Clinical Oncology , International Myeloma Working Group , Janssen Biotech Inc , Janssen Research Development , Janssen Pharmaceutical Companies , American Society For Transplantation , Janssen Pharmaceutical Companies Of Johnson , American Society Of Hematology , Clinical Research , Committee For Medicinal Products Human Use , American Cancer Society , None Of The Janssen Pharmaceutical Companies , University Of Manchester , European Commission , Exchange Commission , American Society Of Hematology Meeting , Companies Of Johnson , European Commission Grants Marketing Authorisation , European Medicines Agency , Johnson , Initial Phase , Annual Meeting , New Orleans , Consultant Haematologist , Honorary Senior Lecturer , Christie Hospital , Area Lead Haematology , Evaluating Teclistamabin Relapsed , Refractory Multiple Myeloma , Vice President , Janssen Research , Common Terminology Criteria , Adverse Events , American Society , Cellular Therapy , Medicinal Products , Human Use , Product Characteristics , Janssen Biotech , Pharmaceutical Companies , Infectious Diseases , Janssen Cilag Limited , Private Securities Litigation Reform Act , Janssen Pharmaceutica , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Subcutaneous Daratumumab , Multiple Myeloma , One Cohort , Hematology Meeting , Participants With Multiple Myeloma , Compare Teclistamab , Combination With Daratumumab , B Cell Maturation Antigen , Correlative Analyses , Participants With Relapsed , Cytokine Release Syndrome Using , Physiologically Based Pharmacokinetic Model , Case Study , Population Pharmacokinetics , Exposure Response Relationship Support , Refractory Multiple , Escalation Study , Subcutaneous Daratumumab Regimens , Bispecifict Cell Redirection Antibodies , Daratumumab Subcutaneously , Versus Daratumumab , Commission Grants Marketing Authorisation , Subcutaneous Formulation , Dexamethasone Versus Bortezomib , Patients With Previously Treated Multiple Myeloma , Three Year Follow Up , Lymphoma Myeloma , Today Population Factsheets , Janssen Emea ,

© 2025 Vimarsana